Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis.

ABSTRACT:

Background

The biological mechanisms underlying the differential response to abatacept in patients with rheumatoid arthritis (RA) are unknown. Here, we aimed to identify cellular, transcriptomic, and proteomic features that predict resistance to abatacept in patients with RA.

Methods

Blood samples were collected from 22 RA patients treated with abatacept at baseline and after 3 months of treatment. Response to treatment was defined by the European League Against Rheumatism (EULAR) response criteria at 3 months, and seven patients were classified as responders and the others as non-responders. We quantified gene expression levels by RNA sequencing, 67 plasma protein levels, and the expression of surface molecules (CD3, 19, and 56) by flow cytometry. In addition, three gene ex

SUBMITTER: Iwasaki T 

PROVIDER: S-EPMC10759752 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature